Based on exploratory experiments (Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/JCI173495DS1), we hypothesized that GLP1R blockade would increase fasting glucagon and glucose concentrations in people with type 2 diabetes but not in those without diabetes. Here, GCG is linked to type 2 diabetes mellitus.